Immunosuppression and HCV recurrence after liver transplantation

Journal of Hepatology

Volumn 56, Issue 4, 2012, Pages 973-983

  Samonakis, Dimitrios N ^a   Germani, Giacomo ^a   Burroughs, Andrew K ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

HCV; Immunosuppression; Liver transplant

Indexed keywords

ALEMTUZUMAB; ALPHA2B INTERFERON; ANTIVIRUS AGENT; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; LYMPHOCYTE ANTIBODY; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PEGINTERFERON; PREDNISONE; RAPAMYCIN; RIBAVIRIN; TACROLIMUS; THYMOCYTE ANTIBODY; VIRUS RNA;

ARTICLE; CORTICOSTEROID THERAPY; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG WITHDRAWAL; FOLLOW UP; GRAFT SURVIVAL; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER FIBROSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; META ANALYSIS (TOPIC); ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; PORTAL HYPERTENSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT INFECTION; SURVIVAL RATE; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; VIRUS HEPATITIS;

EID: 84858698951     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2011.06.031     Document Type: Note

References (91)

1. N.A. Terrault, M.L. Shiffman, A.S. Lok, S. Saab, L. Tong, and R.S. Brown Jr. Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation Liver Transpl 13 2007 122 129 (Pubitemid 46099981)
2. K. Watt, B. Veldt, and M. Charlton A practical guide to the management of HCV infection following liver transplantation Am J Transplant. 9 2009 1707 1713
3. Berenguer M, Prieto M, Rayon JM, Mora J, Pastor M, Ortiz V, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000;32:852-58.
4. G. Kalambokis, P. Manousou, D. Samonakis, F. Grillo, A.P. Dhillon, and D. Patch Clinical outcome of HCV-related graft cirrhosis and prognostic value of hepatic venous pressure gradient Transpl Int 22 2009 172 181
5. G.W. McCaughan, N.A. Shackel, P. Bertolino, and D.G. Bowen Molecular and cellular aspects of hepatitis C virus reinfection after liver transplantation: how the early phase impacts on outcomes Transplantation 87 2009 1105 1111
6. B. Roche, and D. Samuel Risk factors for hepatitis C recurrence after liver transplantation J Viral Hepat 14 2007 89 96 (Pubitemid 47624117)
7. M. Berenguer, A. Royuela, and J. Zamora Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis Liver Transpl 13 2007 21 29 (Pubitemid 46099970)
8. Berenguer M, Crippin J, Gish R, Bass N, Bostrom A, Netto G, et al. A model to predict severe HCV-related disease following liver transplantation. Hepatology 2003;38:34-41. (Pubitemid 36775793)
9. R. Gedaly, T.M. Clifford, P.P. McHugh, H. Jeon, T.D. Johnston, and D. Ranjan Prevalent immunosuppressive strategies in liver transplantation for hepatitis C: results of a multi-center international survey Transpl. Int. 21 2008 867 872
10. I. Perry, and J. Neuberger Immunosuppression: towards a logical approach in liver transplantation Clin Exp Immunol 139 2005 2 10 (Pubitemid 40066121)
11. Y.H. Oo, T. Dudley, P. Nightingale, G. Haydon, and D. Mutimer Tacrolimus and cyclosporin doses and blood levels in hepatitis C and alcoholic liver disease patients after liver transplantation Liver Transpl 14 2008 81 87 (Pubitemid 351167993)
12. M. Nakagawa, N. Sakamoto, Y. Tanabe, T. Koyama, Y. Itsui, and Y. Takeda Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins Gastroenterology 129 2005 1031 1041 (Pubitemid 41242693)
13. Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003;38:1282-88. (Pubitemid 37314838)
14. D.N. Samonakis, C.K. Triantos, U. Thalheimer, A. Quaglia, G. Leandro, and R. Teixeira Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation Liver Transpl 11 2005 386 395 (Pubitemid 40533206)
15. P. Manousou, A. Dhillon, E. Cholongitas, D. Samonakis, G. Isgro, and V. Calvaruso J Hepatol 54 2011 S227
16. K.G. O'Leary JG, M. Neri, L.W. Jennings, G.J. McKenna, G.L. Davis, and J.F. Trotter Tacrolimus improves survival in hepatits C patients after liver transplantation Hepatology 52 2010 1065 (834 A)
17. W. Irish, S. Arcona, D. Bowers, and J.F. Trotter Cyclosporine versus Tacrolimus Treated Liver Transplant Recipients with Chronic Hepatitis C: outcomes Analysis of the UNOS/OPTN Database Am J Transpl 11 2011 1676 1685
18. M. Cescon, G.L. Grazi, A. Cucchetti, G. Vetrone, M. Ravaioli, and G. Ercolani Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation Liver Transpl 15 2009 782 789
19. R.J. Firpi, H. Zhu, G. Morelli, M.F. Abdelmalek, C. Soldevila-Pico, and V.I. Machicao Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation Liver Transpl 12 2006 51 57
20. N. Selzner, E.L. Renner, M. Selzner, O. Adeyi, A. Kashfi, and G. Therapondos Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome Transplantation 88 2009 1214 1221
21. V.S.M. Vero, L. Pasulo, F.R. Ponziani, R. Vigano, M. Marino, and M.F. Donato J Hepatol 54 2011 S235
22. M.C.N. Rendina, S. Fagiuoli, F. Ponziani, R. Vigano, R.M. Iemmolo, and M.F. Donato Acute and chronic rejection during interferon therapy in HCV recurrent transplant patients: results from AISF-RECOLT-C group J Hepatol 54 2011 S230
23. S. Eguchi, M. Takatsuki, A. Soyama, M. Hidaka, H. Tokai, and K. Hamasaki Intentional conversion from tacrolimus to cyclosporine for HCV-positive patients on preemptive interferon therapy after living donor liver transplantation Ann Transpl 12 2007 11 15
24. K. Inoue, K. Sekiyama, M. Yamada, T. Watanabe, H. Yasuda, and M. Yoshiba Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial J Gastroenterol 38 2003 567 572 (Pubitemid 36857388)
25. X.A. Zervos, D. Weppler, G.P. Fragulidis, M.B. Torres, J.R. Nery, and M.F. Khan Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation Transplantation 65 1998 1044 1046 (Pubitemid 28208421)
26. P. Martin, R.W. Busuttil, R.M. Goldstein, J.S. Crippin, G.B. Klintmalm, and W.E. Fitzsimmons Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial Liver Transpl 10 2004 1258 1262 (Pubitemid 39406080)
27. M.G. Gonzalez, C.P. Madrazo, A.B. Rodriguez, M.G. Gutierrez, J.I. Herrero, and J.M. Pallardo An open, randomized, multicenter clinical trial of oral tacrolimus in liver allograft transplantation: a comparison of dual vs. triple drug therapy Liver Transpl 11 2005 515 524
28. C. Margarit, I. Bilbao, L. Castells, I. Lopez, L. Pou, and E. Allende A prospective randomized trial comparing tacrolimus and steroids with tacrolimus monotherapy in liver transplantation: the impact on recurrence of hepatitis C Transpl Int 18 2005 1336 1345 (Pubitemid 41726729)
29. M. Berenguer, V. Aguilera, M. Prieto, F. San Juan, J.M. Rayon, and S. Benlloch Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients Liver Transpl 12 2006 762 767
30. P. Manousou, D. Samonakis, E. Cholongitas, D. Patch, J. O'Beirne, and A.P. Dhillon Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy Liver Transpl 15 2009 1783 1791
31. D.N. Samonakis, M. Mela, A. Quaglia, C.K. Triantos, U. Thalheimer, and G. Leandro Rejection rates in a randomised trial of tacrolimus monotherapy versus triple therapy in liver transplant recipients with hepatitis C virus cirrhosis Transpl Infect Dis 8 2006 3 12
32. R.J. Firpi, C. Soldevila-Pico, G.G. Morelli, R. Cabrera, C. Levy, and V.C. Clark The use of cyclosporine for recurrent hepatitis C after liver transplant: a randomized pilot study Dig Dis Sci 55 2010 196 203
33. J.A. Carrion, M. Navasa, M. Garcia-Retortillo, J.C. Garcia-Pagan, G. Crespo, and M. Bruguera Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study Gastroenterology 132 2007 1746 1756 (Pubitemid 46695723)
34. M. Berenguer, V. Aguilera, F. San Juan, S. Benlloch, A. Rubin, and R. Lopez-Andujar Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients Transplantation 90 2010 1204 1209
35. V.C. McAlister, E. Haddad, E. Renouf, R.A. Malthaner, M.S. Kjaer, and L.L. Gluud Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis Am J Transplant 6 2006 1578 1585 (Pubitemid 43945797)
36. Haddad EM, McAlister VC, Renouf E, Malthaner R, Kjaer MS, Gluud LL. Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst Rev 2006:CD005161.
37. Berenguer M, Prieto M, San Juan F, Rayon JM, Martinez F, Carrasco D, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002;36:202-10. (Pubitemid 34700779)
38. G. Levy, G.L. Grazi, F. Sanjuan, Y. Wu, F. Muhlbacher, and D. Samuel 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus Liver Transpl 12 2006 1464 1472 (Pubitemid 44594275)
39. F. Villamil, G. Levy, G.L. Grazi, S. Mies, D. Samuel, and F. Sanjuan Long-term outcomes in liver transplant patients with hepatic C infection receiving tacrolimus or cyclosporine Transplant Proc 38 2006 2964 2967 (Pubitemid 44737930)
40. U.P. Neumann, T. Berg, M. Bahra, D. Seehofer, J.M. Langrehr, and R. Neuhaus Fibrosis progression after liver transplantation in patients with recurrent hepatitis C J Hepatol 41 2004 830 836 (Pubitemid 39434314)
41. S.D. Henry, H.J. Metselaar, J. Van Dijck, H.W. Tilanus, and L.J. Van Der Laan Impact of steroids on hepatitis C virus replication in vivo and in vitro Ann NY Acad Sci 1110 2007 439 447 (Pubitemid 350043033)
42. E.J. Gane, B.C. Portmann, N.V. Naoumov, H.M. Smith, J.A. Underhill, and P.T. Donaldson Long-term outcome of hepatitis C infection after liver transplantation N Engl J Med 334 1996 815 820 (Pubitemid 26099603)
43. M. Berenguer, L. Ferrell, J. Watson, M. Prieto, M. Kim, and M. Rayon HCV-related fibrosis progression following liver transplantation: increase in recent years J Hepatol 32 2000 673 684 (Pubitemid 30180389)
44. Prieto M, Berenguer M, Rayon JM, Cordoba J, Arguello L, Carrasco D, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 1999;29:250-56.
45. U.P. Neumann, T. Berg, M. Bahra, G. Puhl, O. Guckelberger, and J.M. Langrehr Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up Transplantation 77 2004 226 231 (Pubitemid 38155751)
46. M. Berenguer, V. Aguilera, M. Prieto, F. San Juan, J.M. Rayon, and S. Benlloch Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression J Hepatol 44 2006 717 722
47. M. Vivarelli, P. Burra, G. La Barba, D. Canova, M. Senzolo, and A. Cucchetti Influence of steroids on HCV recurrence after liver transplantation: a prospective study J Hepatol 47 2007 793 798 (Pubitemid 350051119)
48. S. Brillanti, M. Vivarelli, N. De Ruvo, A.A. Aden, V. Camaggi, and A. D'Errico Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation Liver Transpl 8 2002 884 888 (Pubitemid 35154016)
49. F. Filipponi, F. Callea, M. Salizzoni, G.L. Grazi, L.R. Fassati, and M. Rossi Double-blind comparison of hepatitis C histological recurrence Rate in HCV+ Liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and AZAthioprine Transplantation 78 2004 1488 1495 (Pubitemid 39552935)
50. S. Marubashi, K. Dono, H. Nagano, C. Kim, T. Asaoka, and N. Hama Steroid-free living donor liver transplantation in adults: impact on hepatitis C recurrence Clin Transpl 23 2009 904 913
51. G.B. Klintmalm, W.K. Washburn, S.M. Rudich, T.G. Heffron, L.W. Teperman, and C. Fasola Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study Liver Transpl 13 2007 1521 1531 (Pubitemid 350168192)
52. L. Llado, J. Fabregat, J. Castellote, E. Ramos, X. Xiol, and J. Torras Impact of immunosuppression without steroids on rejection and hepatitis C virus evolution after liver transplantation: results of a prospective randomized study Liver Transpl 14 2008 1752 1760
53. T. Kato, J.J. Gaynor, H. Yoshida, M. Montalvano, H. Takahashi, and N. Pyrsopoulos Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year Transplantation 84 2007 829 835 (Pubitemid 351338942)
54. N. Weiler, I. Thrun, M. Hoppe-Lotichius, T. Zimmermann, I. Kraemer, and G. Otto Early steroid-free immunosuppression with FK506 after liver transplantation: long-term results of a prospectively randomized double-blinded trial Transplantation 90 2010 1562 1566
55. D.L. Segev, S.M. Sozio, E.J. Shin, S.M. NAZArian, H. Nathan, and P.J. Thuluvath Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials Liver Transpl 14 2008 512 525 (Pubitemid 351524408)
56. G. Sgourakis, A. Radtke, I. Fouzas, S. Mylona, K. Goumas, and I. Gockel Corticosteroid-free immunosuppression in liver transplantation: a meta-analysis and meta-regression of outcomes Transpl Int 22 2009 892 905
57. G. Germani, M. Pleguezuelo, F. Villamil, S. Vaghjiani, E. Tsochatzis, and L. Andreana AZAthioprine in liver transplantation: a reevaluation of its use and a comparison with mycophenolate mofetil Am J Transplant 9 2009 1725 1731
58. A. Zekry, M. Gleeson, S. Guney, and G.W. McCaughan A prospective cross-over study comparing the effect of mycophenolate versus AZAthioprine on allograft function and viral load in liver transplant recipients with recurrent chronic HCV infection Liver Transpl 10 2004 52 57 (Pubitemid 38885893)
59. L.I.G. Adreana, G. Germani, M. Pleguezuelo, and A.K. Burroughs Immunosuppression in Liver Transplant Recipients with HCV-related Cirrhosis Org Tiss Cells 12 2009 9 23
60. J. Hunt, F.D. Gordon, W.D. Lewis, E. Pomfret, J.J. Pomposelli, and R.L. Jenkins Histological recurrence and progression of hepatitis C after orthotopic liver transplantation: influence of immunosuppressive regimens Liver Transpl 7 2001 1056 1063 (Pubitemid 34023992)
61. A.J. Eid, R.A. Brown, C.V. Paya, and R.R. Razonable Association between toll-like receptor polymorphisms and the outcome of liver transplantation for chronic hepatitis C virus Transplantation 84 2007 511 516 (Pubitemid 47312163)
62. R. Wiesner, J. Rabkin, G. Klintmalm, S. McDiarmid, A. Langnas, and J. Punch A randomized double-blind comparative study of mycophenolate mofetil and AZAthioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients Liver Transpl 7 2001 442 450 (Pubitemid 32492583)
63. A. Kornberg, B. Kupper, A. Tannapfel, M. Hommann, and J. Scheele Impact of mycophenolate mofetil versus AZAthioprine on early recurrence of hepatitis C after liver transplantation Int Immunopharmacol 5 2005 107 115 (Pubitemid 39626692)
64. R.J. Firpi, D.R. Nelson, and G.L. Davis Lack of antiviral effect of a short course of mycophenolate mofetil in patients with chronic hepatitis C virus infection Liver Transpl 9 2003 57 61 (Pubitemid 36104916)
65. M. Bahra, U.I. Neumann, D. Jacob, G. Puhl, J. Klupp, and J.M. Langrehr MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: impact on histological course Am J Transplant 5 2005 406 411 (Pubitemid 40179529)
66. R.H. Wiesner, J.S. Shorr, B.J. Steffen, A.H. Chu, R.D. Gordon, and J.R. Lake Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C Liver Transpl 11 2005 750 759 (Pubitemid 40975576)
67. J. Lake, D. Patel, K. David, J. Richwine, and J. Morris The association between MMF and risk of progressive renal dysfunction and death in adult liver transplant recipients with HCV Clin Transpl 23 2009 108 115
68. T.M. Manzia, R. Angelico, L. Toti, M.I. Bellini, D. Sforza, and G. Palmieri Long-term, maintenance MMF monotherapy improves the fibrosis progression in liver transplant recipients with recurrent hepatitis C Transpl Int 24 2011 461 468
69. E. Patsenker, V. Schneider, M. Ledermann, H. Saegesser, C. Dorn, and C. Hellerbrand Potent antifibrotic activity of mTOR inhibitors Sirolimus and Everolimus but not of Cyclosporine A and Tacrolimus in experimental liver fibrosis J Hepatol 55 2011 388 398
70. D. Wagner, D. Kniepeiss, S. Schaffellner, E. Jakoby, H. Mueller, and A. Fahrleitner-Pammer Sirolimus has a potential to influent viral recurrence in HCV-positive liver transplant candidates Int Immunopharmacol 10 2010 990 993
71. N.R.C. Nandy, I. Nasser, T.L. Challies, S. Karp, S. Johnson, and D.W. Hanto Impact of Sirolimus based imuunosuppression on fibrosis progression in HCV liver transplant recipients Hepatology 55 2010 151 (395 A)
72. P. De Simone, P. Carrai, A. Precisi, S. Petruccelli, L. Baldoni, and E. Balzano Conversion to everolimus monotherapy in maintenance liver transplantation: feasibility, safety, and impact on renal function Transpl Int 22 2009 279 286
73. P. De Simone, H.J. Metselaar, L. Fischer, J. Dumortier, K. Boudjema, and J. Hardwigsen Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial Liver Transpl 15 2009 1262 1269
74. A.A. Schnitzbauer, C. Zuelke, C. Graeb, J. Rochon, I. Bilbao, and P. Burra BMC Cancer 10 2010 190
75. Toso C, Merani S, Bigam DL, Shapiro AM, Kneteman NM. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 2010;51:1237-43.
76. D.K. Moonka, D. Kim, A. Kapke, K.A. Brown, and A. Yoshida The influence of induction therapy on graft and patient survival in patients with and without hepatitis C after liver transplantation Am J Transplant 10 2010 590 601
77. G.V. Papatheodoridis, S. Davies, A.P. Dhillon, R. Teixeira, J. Goulis, and B. Davidson The role of different immunosuppression in the long-term histological outcome of HCV reinfection after liver transplantation for HCV cirrhosis Transplantation 72 2001 412 418 (Pubitemid 32769624)
78. G.W. McCaughan, and A. Zekry Mechanisms of HCV reinfection and allograft damage after liver transplantation J Hepatol 40 2004 368 374 (Pubitemid 38230834)
79. N. Kamar, J.S. Borde, K. Sandres-Saune, B. Suc, K. Barange, and O. Cointault Induction therapy with either anti-CD25 monoclonal antibodies or rabbit antithymocyte globulins in liver transplantation for hepatitis C Clin Transpl 19 2005 83 89 (Pubitemid 40227857)
80. T.M. Schmitt, M. Phillips, R.G. Sawyer, P. Northup, K.D. Hagspiel, and T.L. Pruett Anti-thymocyte globulin for the treatment of acute cellular rejection following liver transplantation Dig Dis Sci 55 2010 3224 3234
81. A. Marcos, B. Eghtesad, J.J. Fung, P. Fontes, K. Patel, and M. Devera Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus Transplantation 78 2004 966 971 (Pubitemid 39391856)
82. L. Urbani, A. Mazzoni, P. Colombatto, L. Bindi, G. Biancofiore, and C. Tascini A novel immunosuppressive strategy combined with preemptive antiviral therapy improves the eighteen-month mortality in HCV recipients transplanted with aged livers Transplantation 86 2008 1666 1671
83. N. De Ruvo, A. Cucchetti, A. Lauro, M. Masetti, N. Cautero, and F. Di Benedetto Preliminary results of a "prope" tolerogenic regimen with thymoglobulin pretreatment and hepatitis C virus recurrence in liver transplantation Transplantation 80 2005 8 12 (Pubitemid 40980888)
84. Y. Calmus, J.R. Scheele, I. Gonzalez-Pinto, E.J. Jaurrieta, E. Klar, and G.P. Pageaux Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with AZAthioprine-containing triple therapy in liver transplant recipients Liver Transpl 8 2002 123 131 (Pubitemid 34202140)
85. C.B. Ramirez, C. Doria, F. di Francesco, M. Iaria, Y. Kang, and I.R. Marino Basiliximab induction in adult liver transplant recipients with 93% rejection-free patient and graft survival at 24 months Transplant Proc 38 2006 3633 3635 (Pubitemid 44908493)
86. D.R. Nelson, C. Soldevila-Pico, A. Reed, M.F. Abdelmalek, A.W. Hemming, and W.J. Van der Werf Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation Liver Transpl 7 2001 1064 1070 (Pubitemid 34023993)
87. P. Neuhaus, P.A. Clavien, D. Kittur, M. Salizzoni, A. Rimola, and K. Abeywickrama Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial Liver Transpl 8 2002 132 142 (Pubitemid 34202141)
88. E.K. Geissler, and H.J. Schlitt Immunosuppression for liver transplantation Gut 58 2009 452 463
89. A. Sanchez-Fueyo, and T.B. Strom Immunologic basis of graft rejection and tolerance following transplantation of liver or other solid organs Gastroenterology 140 2011 51 64
90. G. Tisone, G. Orlando, A. Cardillo, G. Palmieri, T.M. Manzia, and L. Baiocchi Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence J Hepatol 44 2006 702 709
91. G. Orlando, T. Manzia, L. Baiocchi, A. Sanchez-Fueyo, M. Angelico, and G. Tisone The Tor Vergata weaning off immunosuppression protocol in stable HCV liver transplant patients: the updated follow-up at 78 months Transpl Immunol 20 2008 43 47